5 debts you should pay off now – or later

first_img continue reading » From mortgages to credit cards, all debt is not created equal.by: Geoff WilliamsYou often hear that there’s good debt and bad debt. That’s probably because we’d all be depressed if financial experts went around referring to bad debt and worse debt.After all, it’s challenging to live without owing somebody something. If you want to buy a house with cash, by the time you save up enough, it may be time to head to the retirement home. If you’re saving up to buy a car free and clear, you may have to spend a lot of years riding the bus. Most people get through life by borrowing money.So, sure, there’s good debt (the kind you probably can’t avoid carrying) and there’s bad debt (the kind you should try to get rid of sooner rather than later). One key to determining which debts to pay off now versus later is the interest rate: The lower it is, the longer you can carry the debt without it becoming a burden. Here are some guidelines to help you prioritize your debts.Mortgage: Pay off later.The reasoning. If you have a large mortgage, and you win the lottery or come into an inheritance that allows you to pay your house off easily, doing it now is probably not a bad idea. As Jesse Walton, Jr., a vice president at the Walton Group at Morgan Stanley, says, “Paying off debt early is almost always a positive thing.” That includes mortgages. 4SHARESShareShareSharePrintMailGooglePinterestDiggRedditStumbleuponDeliciousBufferTumblrlast_img read more

BPOM to visit Sinovac’s facility in Beijing as part of COVID-19 vaccine quality control

first_imgIndonesia’s Food and Drug Monitoring Agency (BPOM) is set to visit the facility of China’s pharmaceutical company Sinovac in Beijing to assure the quality of a COVID-19 candidate vaccine currently being developed by the latter, Foreign Affairs Minister Retno LP Marsudi has revealed.“It’s part of our efforts to carefully prepare COVID-19 vaccination in Indonesia,” Retno said through a teleconference on Monday. The country has secured priority access to the vaccine bulk produced by Sinovac, and will start to receive it in November. State-owned pharmaceutical firm Biofarma will then process the bulk, an aqueous form of the purified antigens, into smaller doses of ready-to-use vaccines in its facility in Bandung, West Java. Both companies have closely coordinated in developing the candidate vaccine, dubbed CoronaVac. They launched last month a late-stage human trial for the candidate vaccine involving at least 1,620 Indonesian citizens. Read also: Global coronavirus death toll passes one million“Sinovac visited Bio Farma’s facility in Bandung last week to check out the clinical trial results,” Minister Retno further said, adding that the results turned out to be “good and there were no serious side effects”.In its mid-stage clinical trial involving 600 participants in China, the candidate vaccine did not cause any serious side effects and the rate of fever was relatively low compared to other COVID-19 candidate vaccines, Reuters reported previously.Sinovac has to test its vaccine abroad because China is no longer a suitable site for late-stage trials due to the low number of new infection cases. CoronaVac has also undergone a late-stage trial in Brazil expected to involve 9,000 people.Topics :last_img read more